Dr. John Bream posts new youtube video Dr. Brea
Post# of 148179
Dr. Bream continues to push for approval of Leronlimab. He is hosting a Facebook Live discussion tomorrow (Sunday) night at 7:30 pm CDT on Covid long haulers. No doubt he will discuss Leronlimab.
He posted a new 4 1/2 minute video today discussing Leronlimab and trying to pressure the FDA to approve. The link and description are posted below.
https://www.youtube.com/watch?v=uEdHSu1FUt0
EUA for Leronlimab - THE COVID Lifeline
84 subscribers
I’m doing everything humanly possible for my COVID patients, the FDA is NOT.
The FDA could have Saved Tens of Thousands of American lives, but what did they do instead? Keep Big Pharma happy.
The Philippines got it Right! According to his son, EJ Estrada, the former Philippine President Joseph “ERAP” Estrada “was administered Leronlimab.” The Results are in. The US FDA Knows Leronlimab Saves Lives!
The US FDA has yet to issue an Emergency Use Authorization (EUA) in The US for the best performing drug to save the lives of Critically Ill Covid patients. Leronlimab, by Cytodyn. A US company based in Vancouver, WA with 22 employees.
Leronlimab reduces mortality by 85% in critically ill COVID patients and the safety profile is amazing! These numbers were statistically relevant in a large randomized controlled trial.
What is drawing the ire of doctors in the US is that critically ill patients are 85% more likely to die without leronlimab!!
ER Dr. John Bream "The World Needs Leronlimab to Fight COVID-19"
Dr. John Bream a Board Certified Emergency Room medicine Physician practicing in North Carolina talks about the benefits of a drug called Leronlimab by CytoDyn, a ccr5 receptor antagonist.
Dr. Bream stated, "put very simply the world needs Leronlimab to fight covid-19 at this point the pandemic.” Dr. Bream has seen hundreds if not thousands of patients with coronavirus and has admitted multiple patients to the hospital to die without any hope of a cure.
Once a patient becomes severely ill with covid-19 your options are essentially very limited including Decadron which only has a small reduction and mortality and possibly tocilizumab which is not widely available which also had a small reduction in mortality.
It is Dr. Bream's plea that Leronlimab be provided access to the market for covid-19. The recent phase 3 trial showed that when combined with Decadron the other standard of care drugs that the reduction in mortality was significant and that the length of stay for critically ill patients in the hospital with decreased by 6 days which helps decrease the backlog on the patients in the ICU care also significantly decreases the cost of care.
Leronlimab is up for emergency use authorization (EUA) at this time. Anything you can do to help support this life-changing life-saving molecule will be greatly appreciated. In addition, Leronlimab is being tried on patients suffering from longhaulers.